BACKGROUND: The true incidence of transfusion-associated hepatitis (TAH) before blood screening is unknown. Our aims were to reevaluate blood recipients receiving unscreened blood and analyze hepatitis viruses circulating more than 45 years ago. STUDY DESIGN AND METHODS: Cryopreserved serum samples from 66 patients undergoing open heart surgery in the 1960s were reevaluated with modern diagnostic tests to determine the incidence of TAH and its virologic causes. RESULTS: In this heavily transfused population receiving a mean of 20 units per patient of predominantly paid-donor blood, 30 of 66 (45%) developed biochemical evidence of hepatitis; of these, 20 (67%) were infected with hepatitis C virus (HCV) alone, four (13%) with hepatitis B virus (HBV) alone, and six (20%) with both viruses. Among the 36 patients who did not develop hepatitis, four (11%) were newly infected with HCV alone, nine (25%) with HBV alone, and one (3%) with both viruses. Overall, 100% of patients with hepatitis and 39% of those without hepatitis were infected with HBV and/or HCV; one patient was also infected with hepatitis E virus. The donor carrier rate for HBV and/or HCV was estimated to be more than 6%; contemporaneously prepared pooled normal human plasma was also contaminated with multiple hepatitis viruses. CONCLUSION: TAH virus infections were a larger problem than perceived 50 years ago and HCV was the predominant agent transmitted. All hepatitis cases could be attributed to HCV and/or HBV and hence there was no evidence to suggest that an additional hepatitis agent existed undetected in the blood supply.
BACKGROUND: The true incidence of transfusion-associated hepatitis (TAH) before blood screening is unknown. Our aims were to reevaluate blood recipients receiving unscreened blood and analyze hepatitis viruses circulating more than 45 years ago. STUDY DESIGN AND METHODS: Cryopreserved serum samples from 66 patients undergoing open heart surgery in the 1960s were reevaluated with modern diagnostic tests to determine the incidence of TAH and its virologic causes. RESULTS: In this heavily transfused population receiving a mean of 20 units per patient of predominantly paid-donor blood, 30 of 66 (45%) developed biochemical evidence of hepatitis; of these, 20 (67%) were infected with hepatitis C virus (HCV) alone, four (13%) with hepatitis B virus (HBV) alone, and six (20%) with both viruses. Among the 36 patients who did not develop hepatitis, four (11%) were newly infected with HCV alone, nine (25%) with HBV alone, and one (3%) with both viruses. Overall, 100% of patients with hepatitis and 39% of those without hepatitis were infected with HBV and/or HCV; one patient was also infected with hepatitis E virus. The donor carrier rate for HBV and/or HCV was estimated to be more than 6%; contemporaneously prepared pooled normal human plasma was also contaminated with multiple hepatitis viruses. CONCLUSION:TAH virus infections were a larger problem than perceived 50 years ago and HCV was the predominant agent transmitted. All hepatitis cases could be attributed to HCV and/or HBV and hence there was no evidence to suggest that an additional hepatitis agent existed undetected in the blood supply.
Authors: X J Meng; R H Purcell; P G Halbur; J R Lehman; D M Webb; T S Tsareva; J S Haynes; B J Thacker; S U Emerson Journal: Proc Natl Acad Sci U S A Date: 1997-09-02 Impact factor: 11.205
Authors: Timothy J Davern; Naga Chalasani; Robert J Fontana; Paul H Hayashi; Petr Protiva; David E Kleiner; Ronald E Engle; Hanh Nguyen; Suzanne U Emerson; Robert H Purcell; Hans L Tillmann; Jiezhun Gu; Jose Serrano; Jay H Hoofnagle Journal: Gastroenterology Date: 2011-08-16 Impact factor: 22.682
Authors: Giacomo Diaz; Ronald E Engle; Ashley Tice; Marta Melis; Stephanie Montenegro; Jaime Rodriguez-Canales; Jeffrey Hanson; Michael R Emmert-Buck; Kevin W Bock; Ian N Moore; Fausto Zamboni; Sugantha Govindarajan; David E Kleiner; Patrizia Farci Journal: Mol Cancer Res Date: 2018-06-01 Impact factor: 5.852
Authors: Zhaochun Chen; Giacomo Diaz; Teresa Pollicino; Huaying Zhao; Ronald E Engle; Peter Schuck; Chen-Hsiang Shen; Fausto Zamboni; Zhifeng Long; Juraj Kabat; Davide De Battista; Kevin W Bock; Ian N Moore; Kurt Wollenberg; Cinque Soto; Sugantha Govindarajan; Peter D Kwong; David E Kleiner; Robert H Purcell; Patrizia Farci Journal: Proc Natl Acad Sci U S A Date: 2018-11-12 Impact factor: 11.205
Authors: Vanessa Meier-Stephenson; Tekalign Deressa; Meaza Genetu; Debasu Damtie; Sheila Braun; Kevin Fonseca; Mark G Swain; Guido van Marle; Carla S Coffin Journal: Can Liver J Date: 2020-11-17
Authors: John R Ticehurst; Nora Pisanic; Michael S Forman; Carly Ordak; Christopher D Heaney; Edgar Ong; Jeffrey M Linnen; Paul M Ness; Nan Guo; Hua Shan; Kenrad E Nelson Journal: Transfusion Date: 2019-01-31 Impact factor: 3.157
Authors: Ronald E Engle; Davide De Battista; Emily J Danoff; Hanh Nguyen; Zhaochun Chen; Paolo Lusso; Robert H Purcell; Patrizia Farci Journal: mBio Date: 2020-11-17 Impact factor: 7.867